• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Schulman IRB adds Biosafety Officer Daniel Eisenman

Schulman IRB adds Biosafety Officer Daniel Eisenman

January 26, 2017
CenterWatch Staff

Schulman IRB, a central IRB in customer service and technology, announced that Daniel Eisenman, Ph.D., RBP, SM (NRCM), CBSP, has joined the organization as Biosafety Officer.

In his new role, Dr. Eisenman will work with Schulman leadership to develop and manage a forthcoming institutional biosafety committee (IBC) service. He will also provide consulting services for research organizations navigating the IBC landscape. The new IBC service represents Schulman's response to many requests from research sponsors and institutions seeking an independent option for establishing IBCs when required by federal regulations.

"We're delighted to work with someone so experienced and knowledgeable as Dr. Eisenman," said Michael Woods, president and CEO of Schulman IRB. "He has already built and managed several biosafety programs and worked with many IBCs. He has a knack for explaining complex concepts in a clear, understandable manner. All of this makes him the ideal leader for Schulman's IBC services."

Dr. Eisenman previously served as Biological Safety Officer, Alternate Responsible Official for CDC select agents, and Institutional Contact for Dual Use Research at the University of North Carolina Chapel Hill. He has served on multiple institutional biosafety committees and BSL-3 oversight committees as well as consulted for multiple IACUC committees.

Schulman's commercial IBC service will launch in the spring of 2017.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing